Patents Examined by Suzanne Ziska
-
Patent number: 9757547Abstract: A blood coagulating device can include an absorbent body; and a hemostatic lysine composition associated with the body. The body can have a cylindrical or conical member having a first end having the hemostatic composition, the first end being configured for insertion into a nasal passageway. A method for coagulating blood can include providing a powdered hemostatic lysine composition; and applying the powdered hemostatic lysine composition to blood so as to cause the blood to coagulate and form a clot. The coagulation can occur in a nasal passageway away from a blood vessel. The method can include providing at least one absorbent member having the powdered hemostatic lysine composition; and applying the at least one absorbent member to the blood so that the powdered hemostatic lysine composition causes the blood to coagulate and clot.Type: GrantFiled: May 2, 2014Date of Patent: September 12, 2017Assignee: Park City Bio, LLCInventors: Jonathan M. Benns, Matthew C. Lawyer
-
Patent number: 9757349Abstract: Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.Type: GrantFiled: August 10, 2016Date of Patent: September 12, 2017Assignee: FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANONInventors: Alberto Tejedor Jorge, Alberto Lazaro Fernandez, Sonia Camano Paez, Ana Maria Torres Redondo, Jose Antonio Lazaro Manero, Manuela Castilla Barba, Maria del Carmen De Lucas Collantes
-
Patent number: 9757544Abstract: The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.Type: GrantFiled: March 11, 2016Date of Patent: September 12, 2017Assignee: Lutonix, Inc.Inventor: Lixiao Wang
-
Patent number: 9750688Abstract: The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol and existing in gel form in aqueous solution at a concentration ?1% at 25° C. and neutral pH and having a melting temperature (gel to sol) of 35 to 60° C. when the glucan is dissolved in water at a concentration of 2%, methods for the production thereof, medical uses thereof, physical supports having the glucan applied thereto or impregnated thereon and in vitro methods of proliferation of skin cells which comprise contacting a population of skin cells with the glucan.Type: GrantFiled: March 10, 2016Date of Patent: September 5, 2017Assignee: BIOTEC PHARMACON ASAInventors: Rolf Engstad, Stein-Tore Solem, Dag-Eirik Ramsøy
-
Patent number: 9750704Abstract: The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.Type: GrantFiled: February 12, 2013Date of Patent: September 5, 2017Assignee: Diurnal LimitedInventors: Hiep Huatan, Richard Ross, Martin Whitaker
-
Patent number: 9750840Abstract: A bone cement comprising a first component and a second component, wherein contacting the first component and the second component produces a mixture which attains a high viscosity an initial period and the viscosity of the mixture remains relatively stable for a working time of at least 5 minutes after the initial setting period, and the mixture is suitable for in-vivo use.Type: GrantFiled: December 20, 2012Date of Patent: September 5, 2017Assignee: DePuy Synthes Products, Inc.Inventors: Mordechay Beyar, Oren Globerman, Ronen Shavit, Hila Wachsler-Avrahami
-
Patent number: 9750697Abstract: A composition for use as a topical delivery system for an active material is provided, the composition comprising a plurality of skin cell removal particles and a plurality of active material molecules, at least some of the skin cell removal particles each carrying at least one active material molecule, wherein carrying of an active material molecule by a skin cell removal particle maintains activity of the active material molecule. A topical delivery system for an active material, and a method of topical delivery of an active material are also provided.Type: GrantFiled: July 27, 2012Date of Patent: September 5, 2017Assignee: SiSaf LimitedInventors: Roghieh Saffie-Siebert, Nasrollah Torabi-Pour
-
Patent number: 9750851Abstract: An implantable medical device including at least one double-walled microsphere containing an active agent, and a biodegradable polymer layer containing the at least one double-walled microsphere.Type: GrantFiled: October 26, 2016Date of Patent: September 5, 2017Assignee: University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: Lauren Elizabeth Kokai, Kacey Gribbin Marra
-
Patent number: 9744113Abstract: Compositions for delivering materials, such as a biological material, sand, soil, metal, water, sea water, holy water, synthetic or biological polymers, cremated ash, ceramics, animal or plant tissue, or another physiologically compatible component having personal significance to an individual are described herein. The material(s) are encapsulated in an inert, non-bioerodible, hydrophobic, polymeric material. Methods of making microparticles encapsulating the personalizing substance and methods of use are also provided. The personalizing substance may be encapsulated in a polymeric non-bioerodible microparticle. The encapsulated personalizing substance may be combined with a carrier for delivery to an individual's skin. In some embodiments, the personalizing substance is added to a tattoo ink and incorporated in a tattoo created on an individual's skin. Following injection in the skin, the encapsulated material remains in the microparticles, and is not released over time.Type: GrantFiled: February 24, 2017Date of Patent: August 29, 2017Assignee: Chamber Works, LLCInventors: Patrick Duffy, Ellen Dias Jorgensen, Erich Boger, Edith Mathiowitz
-
Patent number: 9744123Abstract: Tissue implants prepared for the repair of tissues, especially avascular tissues such as cartilage. One embodiment presents an electric potential capable of receiving and accumulating desirable factors or molecules from surrounding fluid when exposed to dynamic loading. In another embodiment the implant promotes tissue conduction by retarding, restricting and controlling cellular invasion through use of gradients until competent tissue forms. Further embodiments of the tissue implants may be formed into a multi-phasic device that provides deep tissue mechanical stimulus by conduction of mechanical and fluid forces experienced at the surface of the implant.Type: GrantFiled: June 30, 2009Date of Patent: August 29, 2017Assignee: KENSEY NASH CORPORATIONInventors: Emme M. Castiglione-Dodd, Gino Bradioa, Ali Ebrahiml, Timothy A. Ringeisen
-
Patent number: 9737645Abstract: A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.Type: GrantFiled: December 15, 2015Date of Patent: August 22, 2017Assignee: Micell Technologies, Inc.Inventors: James P. DeYoung, Charles Douglas Taylor, James B. McClain, Clint Smoke, Mike Cole
-
Patent number: 9737640Abstract: Medical device are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is water-soluble. In further embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has a molecular weight of from 80 to 750 or has more than four hydroxyl groups.Type: GrantFiled: May 13, 2016Date of Patent: August 22, 2017Assignee: Lutonix, Inc.Inventor: Lixiao Wang
-
Patent number: 9737691Abstract: Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.Type: GrantFiled: May 13, 2016Date of Patent: August 22, 2017Assignee: Lutonix, Inc.Inventor: Lixiao Wang
-
Patent number: 9730909Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.Type: GrantFiled: March 21, 2011Date of Patent: August 15, 2017Assignee: BOSTON BIOMEDICAL, INCInventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
-
Patent number: 9724304Abstract: Provided is a nanosphere for delivery of a therapeutic agent comprising: a polymer matrix; discrete liquid oil droplets dispersed in the polymer matrix; and a therapeutic agent dissolved or dispersed in the oil. In some embodiments, the nanosphere is pegylated. In some embodiments, the nanosphere has a diameter of from about 100 nm to about 300 nm. In further preferred embodiments, the nanosphere has a diameter of from about 150 nm to about 250 nm. In yet further embodiments, the nanosphere has a diameter of from about 180 nm to about 220 nm. In some embodiments, the oil comprises a lipid or a phospholipid. In further embodiments, the lipid or the phospholipid has a melting point below 20° C. In some embodiments, the polymer is a natural, modified or synthetic polymer. In further embodiments, the polymer is biodegradable.Type: GrantFiled: June 14, 2013Date of Patent: August 8, 2017Assignee: TEMPLE UNIVERSITY—Of The Commonwealth System of Higher EducationInventors: Ho Lun Wong, Mayuri Narvekar, Hui Yi Xue
-
Patent number: 9724306Abstract: Devices and methods for substantially reducing the caloric efficiency of the digestive tract by capturing food being digested in the stomach 10 and/or anywhere else in the gastrointestinal (GI) tract, absorbing or encapsulating the captured food into multiple capturing members and moving such multiple capturing members containing the ingestible encapsulated food down the GI tract, practically out of reach of the GI absorption organs, thus excluding the entrapped ingredients from being involved in the digestion and\or absorption process. The device is designed for oral delivery. The system can be comprised of liquid, food bars or a capsule system. The capsule system is comprised of an external capsule that dissolves in accordance with a temporal or ph dependent preset, which allows the food intake to be at least partially fluidic. The capsule system is further comprised of a mechanism designed to capture and isolate a portion of the food being digested.Type: GrantFiled: December 29, 2015Date of Patent: August 8, 2017Assignee: SLENDINE AGInventors: Amir Alon, Itzhak Katz, Benjamine Alspector, Abraham J. Domb
-
Patent number: 9713643Abstract: The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents.Type: GrantFiled: May 8, 2014Date of Patent: July 25, 2017Assignee: Foamix Pharmaceuticals Ltd.Inventors: Doron Friedman, Alex Besonov, Dov Tamarkin, Meir Eini
-
Patent number: 9707315Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.Type: GrantFiled: August 26, 2015Date of Patent: July 18, 2017Assignee: Covidien LPInventors: Steven Bennett, Nathaniel Mast, Kevin Lavigne, Walter Skalla, Saumya Banerjee, Timothy Sargeant, Joshua Stopek
-
Patent number: 9700602Abstract: Microparticle formulations of a sialidase fusion protein are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions.Type: GrantFiled: May 16, 2016Date of Patent: July 11, 2017Assignee: Ansun Biopharma, Inc.Inventors: Michael P. Malakhov, Tiejun Li
-
Patent number: 9700579Abstract: The invention provides a method of treatment comprising reducing therapy-induced adverse effects (TIAE), including chemotherapy-induced adverse effects (CIAE), such as chemotherapy-induced peripheral neuropathy (CIPN) and/or chemotherapy-induced cardiovascular adverse effects (CICAE) in a subject being treated with a CIAE-inducing anti-cancer active ingredient by co-administering to the subject a pharmaceutically effective amount of a NCS-1-protective composition. Related pharmaceutical compositions, diagnostics and screening techniques are also provided.Type: GrantFiled: April 27, 2012Date of Patent: July 11, 2017Assignee: YALE UNIVERSITYInventors: Barbara Ehrlich, Sara Rockwell, Jennifer Benbow